CDX2 and cancer: However, the fact that most colorectal cancers that diffusely express Cdx2 also do so in their metastases (as the marker may be used diagnostically for cancers of unknown primary as a marker of intestinal differentiation) supports the notion of tumor redifferentiation and reversibility of EMT at metastatic sites.